Information  X 
Enter a valid email address

HutchisonChnMedtechLtdOrd USD1 (HCM)

Date Time Source Announcement
15 Apr 2019 7:30 am
RNS
Disclosure Update
  7:00 am
RNS
HK Listing Application - Proposed Global Offering
29 Mar 2019 7:00 am
RNS
Start of Phase IIb/III Surufatinib Trial in China
28 Mar 2019 7:30 am
RNS
Savolitinib Lung Cancer Presentations at AACR
25 Mar 2019 7:00 am
RNS
Vesting of awards under Long Term Incentive Plan
21 Mar 2019 7:00 am
RNS
Chi-Med 2018 Annual Report and Notice of AGM
11 Mar 2019 12:54 pm
RNS
Publication of Form 20-F
  7:00 am
RNS
2018 FY Results and Key Clinical Programs Update
12 Feb 2019 7:00 am
RNS
Savolitinib PRCC Data to be presented at ASCO GU
08 Feb 2019 7:00 am
RNS
Chi-Med to Announce 2018 Final Results
07 Jan 2019 7:00 am
RNS
Chi-Med Presents at JPM Healthcare Conference
31 Dec 2018 7:00 am
RNS
Blocklisting Six Monthly Return
  7:00 am
RNS
Total Voting Rights
24 Dec 2018 12:41 pm
RNS
Second Price Monitoring Extn
  12:36 pm
RNS
Price Monitoring Extension
20 Dec 2018 7:13 am
RNS
Chi-Med announce Savolitinib program update
  7:00 am
RNS
Amendment to Lilly Agreement on Fruquintinib
14 Dec 2018 7:21 am
RNS
TR-1: Form for notification of major holdings
30 Nov 2018 7:00 am
RNS
Total Voting Rights
29 Nov 2018 8:00 am
RNS
Chi-Med Enters into Multiple Collaborations
26 Nov 2018 7:00 am
RNS
First Commercial Launch of Fruquintinib Capsules
16 Nov 2018 7:00 am
RNS
Phase III FALUCA Trial Results for Fruquintinib
31 Oct 2018 7:00 am
RNS
Total Voting Rights
22 Oct 2018 10:05 am
RNS
Grant of Share Options under Share Option Scheme
18 Oct 2018 7:00 am
RNS
Chi-Med Initiates a Ph I Trial of HMPL-523 for AML
05 Oct 2018 7:00 am
RNS
Appointment of HSBC Bank plc as Broker in London
05 Sep 2018 7:00 am
RNS
Fruquintinib Approved for CRC in China
31 Aug 2018 7:00 am
RNS
Total Voting Rights
07 Aug 2018 10:00 am
RNS
Grant of Share Options under Share Option Scheme
27 Jul 2018 7:00 am
RNS
2018 Interim Results and Clinical Programs Update
23 Jul 2018 7:00 am
RNS
Start of Sulfatinib US Phase Ib/II PoC trial
29 Jun 2018 7:02 am
RNS
Total Voting Rights
  7:01 am
RNS
Blocklisting Six Monthly Return
  7:00 am
RNS
Chi-Med to Announce Half-Year Financial Results
07 Jun 2018 10:00 am
RNS
Grant of Share Options under Share Option Scheme
04 Jun 2018 9:41 am
RNS
Further Fruquintinib FRESCO Trial Data - ASCO 2018
31 May 2018 7:00 am
RNS
Total Voting Rights
30 Apr 2018 7:00 am
RNS
Total Voting Rights
27 Apr 2018 1:52 pm
RNS
Results of Annual General Meeting
23 Apr 2018 1:10 pm
RNS
Grant of Share Options under Share Option Scheme
  1:05 pm
RNS
Block Admission
29 Mar 2018 7:00 am
RNS
Total Voting Rights
28 Mar 2018 7:00 am
RNS
Vesting of awards under Long Term Incentive Plan
26 Mar 2018 7:00 am
RNS
Annual Report & Notice of Annual General Meeting
21 Mar 2018 9:25 am
RNS
Director's Share Dealing
20 Mar 2018 9:15 am
RNS
Grant of Share Options under Share Option Scheme
19 Mar 2018 7:10 am
RNS
Director's Share Dealing
12 Mar 2018 11:22 am
RNS
Publication of Form 20-F
  7:02 am
RNS
Final Results and Key Clinical Programs Update
06 Mar 2018 7:00 am
RNS
Phase Ib/II Trial of Epitinib in Glioblastoma
13 Feb 2018 7:01 am
RNS
Enrolment completed Ph III FALUCA Fruquintinib
05 Feb 2018 7:00 am
RNS
Chi-Med to Announce 2017 Final Results
29 Dec 2017 7:00 am
RNS
Block listing Interim Review
  7:00 am
RNS
Total Voting Rights
15 Dec 2017 7:00 am
RNS
Chi-Med Initiates Fruquintinib US Clinical Trials
01 Nov 2017 9:45 am
RNS
Notification of Major Holdings
  9:45 am
RNS
NOTIFICATION OF MAJOR HOLDINGS
31 Oct 2017 7:00 am
RNS
FRUTIGA, a Phase III trial of Fruquintinib
30 Oct 2017 3:30 pm
RNS
Closing of U.S. Public Offering of ADSs
27 Oct 2017 12:10 pm
RNS
Chi-Med Announces Over-allotment Option
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t